Resolve Therapeutics and Duke Medical School Initiate Observational Study of Cell-free RNA in Polytrauma Patients
MIAMI--(BUSINESS WIRE)--Resolve Therapeutics, a leader in the emerging field of cell-free nucleic acid therapeutics, today announced a collaboration with the Department of Surgery, Duke University School of Medicine to analyze the role of cell-free RNA (cfRNA) in polytrauma www.resolvetherapeutics.com. A significant number of trauma patients admitted to the hospital each year suffer from polytrauma, with multiple, life-threatening injuries requiring immediate surgical intervention. Many of these patients experience poor clinical outcomes due to Systemic Inflammatory Response Syndrome (SIRS). The mechanism of SIRS in polytrauma patients is not completely understood but the current view holds that that massive tissue injury results in the release of large amounts of RNA into the blood overwhelming the activity of circulating RNase, which protects cells from the inflammatory effects of cfRNA under normal circumstances. The accumulating cfRNA activates several key mechanisms driving local and systemic inflammation which leads to increased morbidity and mortality.
'Preventing systemic inflammation in polytrauma would be a large step forward in the treatment paradigm for these patients,' said Allan D. Kirk, MD, PhD, Chair of the Department of Surgery at Duke University.
Share
Working closely with the world's foremost trauma surgeons at Duke University, Resolve and Duke will conduct an observational study to analyze the presence, structure, and drug targeting of cfRNA in a selected population of polytrauma patients. Based on the results of this work, a proof-of-concept clinical trial with RSLV-132 (a fully human, catalytically active, RNase Fc fusion protein) may be undertaken seeking to improve clinical outcomes for polytrauma patients by removing circulating inflammatory nucleic acids.
'We are thrilled to work with the world class physician scientists within the Duke University School of Medicine and are hopeful our work together may lead to an improvement in the outcome for patients with polytrauma,' commented Dr. James Posada chief executive officer of Resolve Therapeutics. 'Duke Surgery offers a unique environment, coupling state of the art patient care with basic research expertise and infrastructure to enable systematic molecular analysis of plasma-borne inflammatory nucleic acids.'
'Preventing systemic inflammation in polytrauma would be a large step forward in the treatment paradigm for these patients,' said Allan D. Kirk, MD, PhD, Chair of the Department of Surgery at Duke University. 'We look forward to the collaboration with Resolve and learning more about the underlying mechanisms of inflammation in critically injured patients,' he added.
About RSLV-132
RSLV-132 is a safe, fully-human, non-immunosuppressive, non-immunogenic, biologic drug with a three-week serum half-life. The drug is comprised of catalytically active human RNase fused to an engineered Fc region of human IgG1. It is designed to remain in circulation and digest extracellular pathogenic RNA in diseases where the presence of cfRNA drives the inflammatory process. RSLV-132 has proven safe in five clinical trials and has demonstrated improvement in autoimmune symptoms in phase 2 clinical trials in both systemic lupus erythematosus and Sjogren's syndrome.
About Resolve Therapeutics
Resolve is a biopharmaceutical company at the forefront of the emerging field of cell-free nucleic acids in disease. We are developing RSLV-132 and RSLV-145 in a broad range of acute and chronic diseases that are driven by cell-free RNA, cell-free DNA, and Neutrophil Extracellular Traps (NETs). For more information or to discuss our programs please visit: https://resolvetherapeutics.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
WebMD
2 hours ago
- WebMD
The Next-Gen Sweetener You May Be Eating
June 6, 2025 – It's time to add the word "neotame" to your ingredient label watch list, especially if you vape. It's a relatively new artificial sweetener found in every disposable e-cigarette that researchers tested – and the ultra-sweet substance is increasingly being used in food and drink. You probably have heard of aspartame. But neotame is its lesser-known sibling, with just one molecular difference. It showed up in laboratory tests of 11 top disposable e-cigarette brands when researchers from Duke and Yale Universities were trying to figure out what makes the vapes, like Elf and Geek Bars, so, so sweet. Neotame is between 7,000 and 13,000 times sweeter than table sugar and up to 65 times sweeter than aspartame. The sweetened e-cig study results were published this week in The Journal of the American Medical Association, or JAMA. Neotame wasn't found in JUUL or other cartridge-based devices, which have their own checkered ingredient history, including the 2019 finding that the sucralose used in them was linked to the production of toxic aerosols. Even if you don't vape, you may already be consuming neotame, since it's found in baked goods, candy (Mentos, for example), and gum – plus salad dressing, fruit spreads, dairy desserts, and yogurt. It's also used in some flavored sparkling waters and drinks like Tampico Mango Punch. Some researchers have soured on neotame because its use makes e-cigs appealing to young people, and because lab tests show it may harm our intestines when ingested. Why You've Never Heard of Neotame Maybe you saw it on an ingredient label and passed over it sometime in the past two decades. It has zero calories, no nutritional value, and was FDA-approved as a food additive in 2002. It's not listed on disposable e-cigarette packaging. Researchers track these sweeteners. Havovi Chichger, PhD, a professor at Anglia Ruskin University in Cambridge, England, says that for more than four decades, we have been consuming "traditional" artificial sweeteners like acesulfame potassium (Ace-K), sucralose, saccharin, and aspartame. But newer substances like neotame "herald the next generation of sweet additives," she said. The substance was developed in the 1990s in a quest for a more stable sweetener for processed products, and its use has steadily grown, she said. It's even used now in some lip cosmetics that have a sweet flavor and aroma. Neotame has also become the 21st-century spoonful of sugar Mary Poppins sang about: It's used to make some pharmaceuticals more palatable. According to a website about neotame set up by Georgia-based maker NutraSweet Co., neotame has an "ability to mask the taste of supplements, vitamins, bitter food ingredients and active pharmaceuticals. Moreover, its high sweetness intensity allows formulation at very small quantities, leaving ample room for your pharmaceutical ingredients." Neotame is not, however, approved for use in products that are inhaled. Why Neotame Is Used in E-Cigarettes – and in Baked Goods The liquid vaporized by e-cigarettes is heated sometimes as hot as 800 degrees Fahrenheit, said Sven Jordt, PhD, senior author of the JAMA study and a Duke University professor who is an expert in chemical sensory biology. Heating vape liquid can chemically change its ingredients, and neotame's strong sweetness and heat stability seem to have led to its new use in vapes, he said. If a lot of a sweetener is burned up or chemically changed when heated, the desired taste profile can still be achieved if just a bit of the ultra-sweetness remains. "The FDA also has determined that neotame can be used for baking, for example, because it's more heat stable than many of the other sweeteners," Jordt said. "Sweeteners like aspartame or Ace K, they are basically burned at normal baking temperatures. However, with neotame, a large proportion survives baking and likely also survives being vaporized by e-cigarettes." His team is concerned that the sweetness makes the products particularly attractive to kids. It's not used in the few e-cigarettes that are legal to sell in the U.S. and was just found in the disposable ones that are illegal but widely available amid lack of enforcement. "We did this study specifically because this category of disposable e-cigarettes is seeing an explosive growth in sales and use," Jordt said, noting that their nicotine concentration is higher than in older products, and at a fraction of the price. "You buy this once and then you can use it a whole week. And kids are puffing on these all the time," he said. "Some have like 15,000 or 20,000 puffs [compared to a few hundred puffs in the older JUUL devices]. So if you use this continuously, you become really heavily addicted to nicotine … and now we are asking: Is it just the design or is there something else in it that makes them much more attractive to kids to use and make them taste better? And then we found this neotame." The Damage Neotame Can Cause Approval of neotame for use in food products was based on studies on mice and other animals that didn't show any adverse physical effects. But what about the effects on humans? Findings published last year suggest that neotame can damage the human intestine. "Neotame can cause previously healthy gut bacteria to become diseased and invade the gut wall – potentially leading to health issues including irritable bowel syndrome and sepsis – and also cause a breakdown of the epithelial barrier, which forms part of the gut wall," said Chichger, who is a cell and molecular biologist and senior author of the study, which was published in the journal Frontiers in Nutrition. The study showed that neotame can damage the "intestinal epithelium," or lining, by causing the death of epithelial cells. It also damages bacteria commonly found in the gut, she added. "Despite the smaller quantities used, the impact of neotame on the epithelium-microbiota relationship has the potential to cause poor gut health, which in turn could lead to metabolic and inflammatory diseases." The findings were the latest in a line of studies showing the effects of artificial sweeteners on gut health. Another recent study led by Los Angeles-based endocrinologist Ruchi Mathur, MD, linked artificial sweeteners to changes in the microbial composition and diversity in stool and the small intestine. That research, which was published in the journal Cell, didn't include neotame. Changes observed in the gut microbiome's biochemical activity "raise concerns regarding the potential impacts of non-sugar sweeteners on metabolic and gastrointestinal health," said Mathur, who is director of the Diabetes Outpatient Teaching Education Center and a professor of medicine at Cedars-Sinai in California. All the experts interviewed for this article said that while there's not enough data to say for sure that inhaling neotame is bad for you, the existing research suggests reasons to be cautious. When you vape, some of the "smoke" can mix with saliva and get swallowed – so neotame could reach your gut, Chichger said. "In fact, there are other studies which show that e-cigarette fluid can cause the same level of damage that we noted from neotame." Unanswered Questions About Neotame Big questions about neotame: How does it affect the lungs? How can we keep track of how much we've consumed (eating, drinking, or inhaling)? And how much is too much? "These sweeteners are only approved for use in food, but not for inhalation," Jordt said. "We don't know how safe they are if you inhale them every day." Mathur noted that the lungs have their own microbiome, and past studies have shown that vaping alters saliva as well as the nasal cavity microbiome. A large study published in March showed a significant link between exclusive e-cigarette use and development of COPD. The FDA has set daily intake limits for neotame, which is sometimes referred to by the brand name Newtame, and other sweeteners. But experts say there is no labeling requirement that shows consumers how much is included in a product, whether it's food, drink, or vape liquid. Jordt said it's unlikely someone would reach that limit by vaping alone. But if you also eat products with the sweetener, then exceeding that limit becomes more likely. "I do think it is reasonable to assume that there should be consumer awareness and caution, as there is little if any data on what happens when this substance is inhaled," Mathur said. You should also be aware of artificial sweeteners in food and drink, Mathur said. Make a plan with your doctor, especially if eating artificially sweetened foods is part of how you manage your body weight or diabetes. "There is enough data to suggest it is safe to use these non-sugar sweeteners in moderation," Mathur said. "If someone uses artificial sweeteners in non-traditional ways, such as inhaling it through an e-cigarette, they are doing so without the benefit of any good information on the potential long-term consequences of taking in the substance through their airways and down into their lungs or what byproducts may be created in the process."
Medscape
3 days ago
- Medscape
No Safety Advantage to Emergency Robotic Cholecystectomy
TOPLINE: In acute care settings, robotic-assisted cholecystectomy (RAC) and laparoscopic cholecystectomy (LC) resulted in similar rates of bile duct injury, but RAC was associated with higher rates of major postoperative complications, more frequent drain placement, and longer hospital stays than LC. METHODOLOGY: Although some prior studies have raised concerns about increased bile duct injury with RAC vs LC, their relative safety in acute care surgery remains unclear. Researchers conducted a retrospective cohort analysis using commercial claims and encounter data from 2016 to 2021 to compare outcomes between RAC and LC in acute care surgery. The primary outcome was bile duct injury; secondary outcomes included major postoperative complications, the use of a postoperative drain, length of hospital stay, surgical site infections, and conversion to open surgery. TAKEAWAY: Researchers included 844,428 adults (mean age, 45.6 years; 64.9% women), with 35,037 undergoing RAC and being propensity-matched with an equal number of adults who underwent LC. Adoption of RAC increased from 2.2% in 2016 to 8.2% in 2021. Bile duct injury rates were similar between the groups (P = .54). RAC vs LC was associated with higher rates of major postoperative complications (8.37% vs 5.50%; P < .001), an increased use of postoperative drains (0.63% vs 0.48%; P < .001), and a longer median hospital stay (3 vs 2 days; P < .001). Use of intraoperative cholangiograms was more common in the LC than in the RAC group (P < .001), whereas RAC was associated with fewer surgical site infections than LC (0.04% vs 0.09%; P = .02). Conversion to open surgery was uncommon in both the groups. IN PRACTICE: 'Although these results may partly reflect case complexity and selection bias, they do not suggest a clear advantage of RAC over the standard, established laparoscopic cholecystectomy,' the authors wrote. SOURCE: The study was led by Nathnael Abera Woldehana, MD, MPH, Division of Minimally Invasive Surgery, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore. It was published online in JAMA Surgery. LIMITATIONS: The retrospective design may have introduced selection bias and unmeasured confounding factors. The study's generalizability is limited to commercially insured populations. Long-term outcomes such as readmissions, quality of life, and cost-effectiveness were not assessed. DISCLOSURES: Some authors reported receiving conference travel/attendance support, consulting fees, grants, advisory board fees, and speaker fees and having other ties with several organizations and pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
New York Post
3 days ago
- New York Post
‘Exciting' new non-opioid painkiller shows promising results — and doesn't build up tolerance
A real ache-ievement! Duke University researchers have devised a promising, potent pain reliever — seemingly without the harmful side effects and addictive highs of opioids. While opioids interact with numerous cellular pathways, the experimental drug is more selective. SBI-810 targets a receptor in the brain and spinal cord, activating a single pain-relief signal while steering clear of other signals that could trigger troublesome consequences. Advertisement 3 Ru-Rong Ji, an anesthesiology and neurobiology researcher who directs the Duke Anesthesiology Center for Translational Pain Medicine, led the team in developing the painkiller SBI-810. Duke University School of Medicine 'What makes this compound exciting is that it is both analgesic and non-opioid,' said senior study author Ru-Rong Ji, an anesthesiology and neurobiology researcher who directs the Duke Anesthesiology Center for Translational Pain Medicine. '[The receptor] is a promising target for treating acute and chronic pain,' Ji added. Advertisement Chronic pain is a persistent problem in the US. Nearly a quarter of adults, about 62 million, experienced it in 2023. Chronic pain has helped fuel the opioid crisis. About 8.6 million Americans 12 years and older reported misusing prescription opioids in 2023. And almost 70% of the 107,000-plus US drug overdose deaths that year were attributed to opioids such as fentanyl. 3 Chronic pain is a persistent problem in the US, with about 62 million adults experiencing it in 2023. AS/ – Advertisement The good news is that there has been recent progress on this front, with more treatment options and fewer opioid-related deaths. It's too early to tell if SBI-810 can help the cause. The drug has not been thoroughly tested in humans, but the results in mice have been encouraging. Opioids like morphine often lead to tolerance with repeated use, requiring higher or more frequent doses to maintain the same level of pain control. Advertisement SBI-810 relieved pain from surgical incisions, bone fractures and nerve injuries without a buildup of tolerance or constipation, another common opioid side effect. 3 The experimental drug SBI-810 targets a receptor in the brain and spinal cord, activating a single pain-relief signal. mybox – When coupled with small doses of opioids, SBI-810 made them more effective at lower doses. And it's said to work better than the painkillers oliceridine and gabapentin in certain situations. The findings were published recently in the journal Cell. Ji's team has secured several patents for SBI-810 and hopes to start human trials soon.
